Ascletis reported positive topline results from a U.S. Phase II 24-week obesity study of its ASC30 subcutaneous depot formulation A1 (NCT06679959) in 65 participants. The primary endpoint was met, with placebo-adjusted mean weight loss of 6% at week 12 and 8% at week 16 after three monthly doses. Placebo-adjusted mean weight loss was 6% at week 20 and 6% at week 24, following the final dose at week 8. Ascletis said formulation A1 achieved therapeutic drug exposures in obese patients, while formulation A2 did not.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260310-12047100), on March 10, 2026, and is solely responsible for the information contained therein.